2 June, 2019 Program

Founded in 2016, the central theme of the first Boston/Paris Biotechnology Summit in 2017 was an introduction to the biotechnology ecosystems in Boston and Paris, which were also highlighted in terms of innovation and leadership. The Summit®’s framework for its 2018 edition was “from the promise of raising capital to the reality of clinical trials” and featured speakers from the academic, biotech, investor, legal/regulatory and pharma worlds. The objective of the third Boston Biotechnology Summit will be to further ensure that the Summit® provides an efficient and cost-effective forum that will add value for the companies which take part. We aim to achieve this by maintaining a hand-crafted content, maintaining its “human size” and strategically expanding this US-based Summit® to broader European participation.

The central theme, in 2019, of the 3rd Summit will be “Collaboration”.

Collaboration is becoming an increasingly important component in the next stage of biotechnology’s evolution. There are at least three fundamental reasons: First, no single technology is likely to generate all the drug innovations required to treat the complex range of diseases that constitute unmet medical needs in our societies. Second, no single company or type of company can possibly possess all the answers, and third, the risky nature of the economics of biotechnology is such that no single region can achieve results on its own.

2019 Venue


The Wistar Institute

3601 Spruce St, Philadelphia, PA, USA 19104




Executive level speakers from 40 organizations in 5 sessions: Collaboration accross Geographies, AI & Big Data, Wistar Institute model, CNS & Neurology, Immunotherapy and Infectious Diseases. More Speakers will be added soon.

8:00 AM

Registration, Morning Coffee Networking, Personal Greeting of Participants, Speakers load slides.

9:00-9:30 AM

International Program Committee & Organizing Committee 

Soheila Gharakhanian

Welcome to the 3rd Boston Biotechnology Summit, introducing the 2019 Organizing Team. Acknowledgements: 3 years of Support from our Sponsors & new additions.

What do we want to achieve today?

Pravin Chaturvedi, Jennifer Chase, Pierre Courteille, Denis Gauvreau, Annika Pierson, Christine Sarkisian, Heather Steinman.

9:35-10:00 AM

The Wistar Institute Model for Collaboration and Curing Chronic Diseases

Introduction by Soheila Gharakhanian, Summit Principal & Head, Organizing Committee.

Heather Steinman Vice President for Business Development & Executive Director of Technology Transfer, The WISTAR Institute, Philadelphia PA, USA, Steering Committee Member, BIO Convention 2019. Member, Summit Program Committee.

Luis Montaner, Vice President, Scientific Operations. Professor of Immunology & Director HIV Immuno-pathogenesis Laboratory.

10:00-11:00 AM

The Evolution of Collaboration in Biopharma

Moderators:Jennifer Chase, Managing Director, Global Life Sciences Practice, Witt/Kieffer International Ltd, Burlington MA, USA – Pierre Courteille, Vice-President, France-Biotech, Paris, France – Annika Pierson, Chief Operating Officer, German Accelerator Life Sciences, Cambridge MA, USA.

Pravin Chaturvedi, CEO OCEANYX Pharmaceuticals, Chair of the Scientific Advisory Board for NAPO Pharmaceuticals, Woburn MA, USA. 

Horst Domdey, BIO.M & Bavarian Biotechnology network. Co-Founder MediGene, Professor, LMU Munich, Germany. 

John Hallinan, Chief Business Officer, Massachusetts Biotechnology Council (MassBIO), Boston MA, USA.

Sophie Kornowski, Senior Partner, Gurnet Point Capital, Cambridge MA, USA.

John Pottage, Senior Vice President, Chief Scientific & Medical Officer, ViiV Healthcare, [GSK, Pfizer, Shionogi Joint Venture] Collegeville, PA.

11:15 AM-12:30 PM

Collaborating in the Era of Artificial Intelligence, Big Data & Digital Health; What Innovative Treatments are We Capable of Optimally Delivering to Patients, Globally?

Moderators: Pravin Chaturvedi, CEO Oceanyx Pharmaceuticals, Woburn MA, USA, 2019 Summit Guest Program Chair – Denis Gauvreau, Director of Innovation and Business Development at Polytechnique Montréal, Canada – Christine Sarkisian, International Business Development, Co-founder, Canadian Technology Accelerator. Consulate General of Canada, Boston MA, USA.

Philippe Jouvet, Deputy Director of the Research Center and the Scientific Director of the Health Technology Assessment Unit of the Sainte Justine Hospital-University of Montreal.

Lizabeth Leveille, Associate VP, Head BD&L Boston Innovation Hub, Merck Research Laboratories.

Elena Diez Cecilia, Director of BD and R&D Strategy at A2A Pharmaceuticals, NYC, USA.

Veronica Miller, Executive Director, Forum for Collaborative Research, Washington DC & Adj. Professor, University of California, Berkley CA, USA.

Patrick Tricoli, CEO of Nanobiotix Corp, the Nanobiotix US affiliate, Cambridge MA, USA.

Dale C. Van Demark, Partner, Mc Dermott Will & Emery, Washington D.C.

12:30-1:30 PM

Lunch, Networking, Major Sponsor’s one-to-one Meetings, Partnering Conversations, Sponsor Exhibits’ Visit.

~ 10 minutes

Shahin Gharakhanian: It takes a village to develop a safe & efficacious therapeutic agent throughly responding to patient needs.

Shahin Gharakhanian & Pravin Chaturvedi: Sessions #4 & #5 format. Presentation of Pitching Companies.

1:30-2:45 PM

Which Collaborative Approaches will Improve CNS: Central Nervous System, Neurological and Aging-related Complications?

Moderators: Cynthia “Cindy” Lander, CEO Moerae Matrix, Partner, Nascent Enterprises, Boston MA, USA, PhD Neurosciences – Michael Nowak, Managing Partner, Nowak Ventures LLC, Wellesley MA, & CEO Navan Technologies, Inc, South San Francisco, CA, USA.


Retsina Meyer, Expert Advisor & Coach to pitching CEOs/companies. Neuroscientist-innovator-entrepreneur, Cambridge MA, is Advisor & Coach to pitching CEOs.

Steve Davis, CEO, ISOMA TherapeuticsPhiladelphia PA, USA. Molecular stratification system using expression of key transcript variants as a prognostic and diagnostic tool.[GBM: Glioblastoma Multiforme & Diagnostic Platform], WISTAR Institute Spin-Off.

Christophe Gaudin, CEO OP2LYSIS. Boulogne-Billancourt/Paris, France. Technology platform for medical treatment of stroke. [CVA: Cerebro-Vascular Accident Treatment].

Marcia Hendrickson, CEO MITOGENETICSSioux Falls, SD, USA. Regulation of Mitochondrial Dysfunction Technology Platform. [Focus: Alzheimer’s Disease].

Erika Smith, CEO RENETX BIO. New Haven CT, USA. [Fusion protein biologics technology platform. Application to chronic Spinal Cord Injury and other neurological disorders].

Geeta Singh, CEO, MAG OPTICS. Lowell MA/Chicago IL, USA. Ophthalmic device innovator for patient-centric corneal shape changing platform [Ophthalmological Platform], 2018 Finalist @ M2D2 UMass Challenge & MASSMEDIC.


Gilles Avenard, CEO Acticor, 2018 Best Biotechnology Entrepreneur Awardee, France.

Olivier Blin, Professor, Aix-Marseille University, Clinical Pharmacology/Neurology, France. EU Innovative Medicines Initiative Scientific Council.

Paul Hartung, representing Launchpad Ventures LLC, Boston MA.

Lizabeth Leveille, Associate VP, Head, Boston Innovation Hub Business Development & Licencing, Merck Research Laboratories, Boston MA.

Maria Lopez-Bresnahan, VP, Clinical Research for Neurology, Alkermis, Waltham MA.

Bernard “Bernie” Rudnick, Angel Investor & Business Strategist, Capgenic Advisors, MABA: Mid Atlantic Bio Angels group, Newark DE.

3:00-4:15 PM

Have we optimized the Potential of Immune-Based Treatments in Infectious Diseases, Chronic Inflammation & Oncology?


Frederic E. “Rick” Pierce II, FEP Capital Advisers, Cambridge MA – New York – Beijing – Shanghai.- Stephan Ogenstad, President, Statogen Consulting LLC, Fmr. Advisor to Sweden’s Nobel Prize Committee for Medicine.

Khelin Aiken, Attorney, Council in the Life Sciences & FDA practice groups, Mc Dermott Will & Emery, Washington DC.


Expert Advisor & Coach to pitching CEOs/companiesShahin Gharakhanian, Infectious Diseases & Pharmaceutical Medicines MD, Cambridge MA Member IAS: International AIDS Society, IDSA: Infectious Disease Society of America & SPILF: Francophone Infectious Diseases Society.

Pierre Chiarelli, CEO, Biosqual, R&D on original squalamine analogues having double antifungal and antibacterial therapeutic properties representing an innovative new class. Winner, Innov’InMed Award 2017 & BPI: Public Investment Bank Award, both in France.

Elena Diez, Co-Founder & Sr. Mgmt Team Member, A2A Pharmaceuticals). New York, NY, USA. Computational systems, including Artificial Intelligence Platform SCULPT: Systematic Combinatorial Unification of fragments into Libraries against Pharmacological Targets. [Infectious Diseases & other Therapeutic Areas]. Winner Johnson & Johnson Innovation Challenge

Abderrahim Lachgar, CEO, Par’Immune, EuraSanté Lille, France. Parasite-derived protein platform with immunomodulatory properties. [Immunotherapy of Severe Chronic Inflammatory Diseases].

Christopher Locher, CEO, Versatope, Cambridge MA. USA. Genetically engineered probiotics technology platform for targeted delivery of large molecules in vaccines, therapeutics and diagnostics. [Universal Flu & Vaccine Platform]. 2018 MALSC Day 1st Prize & M2D2 UMass Challenge Finalist.

Andrew Luber, President/COO, Virion Therapeutics, DE, USA. Checkpoint inhibitor based Vaccines. Immune-based treatments for virally induced cancers and for common chronic infectious diseases. [Oncology & Chronic Viral Infections Vaccine Platform], A Wistar Spin-Off Company.


Marion Hitchcock, Global External Innovation & Alliances, BAYER, Cambridge MA, USA.

Greg Mannix, VP, Life Science Nation, Boston MA.

Veronica Miller, Executive Director, Forum for Collaborative Research.

Nicola La Monica, Senior Director, Infectious Diseases Scientific Innovation @ Janssen Pharmaceutical Companies of Johnson & Johnson, Boston MA, USA.

John Pottage, Chief Medical & Scientific Officer, ViiV Healthcare, Collegeville PA.

4:20 PM

What have we Learned Today about Effective Collaboration? Is it about Finance, Ideas, People or Technology?

International Program Committee on Podium: Pravin Chaturvedi, Nicola La Monica, Abderrahim Lachgar, Cynthia “Cindy” Lander, Michael Nowak, Stephan Ogenstad, Frederic E. “Rick” Pierce II.

4:45 PM

PRINCIPALS ADJOURN 2019 SUMMIT WITH APPRECIATIONS: Soheila Gharakhanian & Shahin Gharakhanian

Register Today

Ready to register for the Boston Biotechnology Summit? Click the button below to get started with your registration process.